On Tuesday, December 12, Micropos Medical hosted the third open user meeting featuring a presentation on the workflow of implementing SBRT with motion monitoring. Over 40 interested participants joined the webinar on Tuesday evening, organized by Micropos Medical in collaboration with four invited clinicians. The participants were primarily from Europe, with representation from American clinics in the audience as well.
Following a brief introduction by CEO Thomas Lindström, the four different clinics presented their experiences and data after nearly two years of using the Raypilot System. Prof. Stefano Arcangeli from IRCCS in Monza presented impressive data from over 30 patients treated with single-dose radiation therapy for prostate cancer. This approach demonstrated a remarkably low side effect rate. Prof. Arcangeli explained that the catheter used by Raypilot enables urethra sparing treatment during real-time monitoring. This will be crucial in future prostate radiation therapy as side effects are minimized to near zero, according to Prof. Arcangeli.
Next presenter was Prof. Duncan McLaren from Western General University Hospital in Edinburgh. He outlined the goal of jointly initiating a three-fraction study called “Precision,” set to commence in the first quarter of 2024. Already, 5–7 different centers in Europe and the USA are likely to join the study, delivering radiation over only three consecutive days.
Prof. McLaren also discussed the significance of the PACE B Study, presented earlier this year at the ASTRO conference in the United States. With the study and its five-year data, SBRT is expected to become the standard of care in many countries. Gradually in 2024, this transition will occur in several regions in Europe and the USA.
From Salzburg, Dr. Wolf and Medical Physicist Johannes Berchthold presented data from their recently published study examining whether the Raypilot System can replace the insertion of gold markers. According to the study, extremely high stability and accuracy were measured with Raypilot Hypocath. The conclusion is that Raypilot with Hypocath can replace gold markers, representing a significant method improvement for most clinics, both economically and, most importantly, in time saved, as it eliminates the need to send the patient for surgery to insert gold markers.
Lastly, Dr. De Bari from La-Chaux-Des-Fonds in Switzerland presented data from over 40 patients. This work has been submitted for scientific publication and will be released shortly. We learned about the positive reception of the introduction of Raypilot with Hypocath by all patients and that it is now the standard method for treating prostate cancer at the hospital.
In summary, the webinar was once again highly appreciated, serving as a valuable platform for participants and users to ask questions and interact with each other. The feedback was very positive, and Micropos Medical plans to organize more user meetings in the future. The next major user meeting is scheduled for ESTRO in May 2024, in Glasgow. During the spring, Micropos Medical will also participate in several scientific congresses.